There are no adequate and well-controlled studies with the piperacillin/tazobactam combination or with piperacillin or tazobactam alone in pregnant women.

Studies in animals have not shown teratogenicity with piperacillin/tazobactam combination when administered intravenously but have shown reproductive toxicity in rates at maternally toxic doses when administered intravenously or intraperitoneally.

Tazocin cross the placenta. Pregnant women should be treated only if the expected benefit outweighs the possible risks to the pregnant women and the fetus.

Piperacillin is excreted in low concentrations in human milk; tazobactam concentrations in human milk have not been studied. Women who are breastfeeding should be treated only if the expected benefit outweighs the possible risks to the woman and child.

Piperacillin/tazobactam combination when administered intravenously or intraperitoneally has shown reproductive toxicity in rates at maternally toxic doses.